179 related articles for article (PubMed ID: 21137051)
1. Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis.
Petri AL; Simonsen AH; Høgdall E; Christensen IJ; Kjaer SK; Yip C; Risum S; Pedersen AT; Hartwell D; Fung ET; Høgdall C
Proteomics Clin Appl; 2010 Mar; 4(3):304-14. PubMed ID: 21137051
[TBL] [Abstract][Full Text] [Related]
2. Increases urinary HMGA1 in serous epithelial ovarian cancer patients.
Zhou J; Xie M; He H; Shi Y; Luo B; Gong G; Li J; Wang J; Wu X; Wen J
Cancer Biomark; 2015; 15(3):325-31. PubMed ID: 25586095
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
[TBL] [Abstract][Full Text] [Related]
4. Significance of blood and salivary IEX-1 expression in diagnosis of epithelial ovarian carcinoma.
Li Y; Tan C; Liu L; Han L
J Obstet Gynaecol Res; 2018 Apr; 44(4):764-771. PubMed ID: 29431239
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
6. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
7. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
8. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
11. Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma.
Arakawa N; Miyagi E; Nomura A; Morita E; Ino Y; Ohtake N; Miyagi Y; Hirahara F; Hirano H
J Proteome Res; 2013 Oct; 12(10):4340-50. PubMed ID: 23805888
[TBL] [Abstract][Full Text] [Related]
12. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
[TBL] [Abstract][Full Text] [Related]
13. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
[TBL] [Abstract][Full Text] [Related]
14. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
[TBL] [Abstract][Full Text] [Related]
15. The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.
Zuberi M; Khan I; Gandhi G; Ray PC; Saxena A
Tumour Biol; 2016 Aug; 37(8):11259-66. PubMed ID: 26951510
[TBL] [Abstract][Full Text] [Related]
16. Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.
Kurosaki A; Hasegawa K; Kato T; Abe K; Hanaoka T; Miyara A; O'Shannessy DJ; Somers EB; Yasuda M; Sekino T; Fujiwara K
Int J Cancer; 2016 Apr; 138(8):1994-2002. PubMed ID: 26595060
[TBL] [Abstract][Full Text] [Related]
17. Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy.
Hanaoka T; Hasegawa K; Kato T; Sato S; Kurosaki A; Miyara A; Nagao S; Seki H; Yasuda M; Fujiwara K
Mol Diagn Ther; 2017 Apr; 21(2):187-198. PubMed ID: 28160193
[TBL] [Abstract][Full Text] [Related]
18. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
[TBL] [Abstract][Full Text] [Related]
19. [Protein levels and its clinical significance of septin-9 and clusterin in peripheral blood of epithelial ovarian cancer patients].
Lyu N; Yao H; Xiao T; Gao Y; Wu L
Zhonghua Fu Chan Ke Za Zhi; 2015 Sep; 50(9):679-84. PubMed ID: 26675395
[TBL] [Abstract][Full Text] [Related]
20. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
